In a bid to broaden its gene editing capabilities, Vertex Pharmaceuticals has entered into a global multi-target license and option agreement with ImmunoGen to leverage the latter’s antibody-drug conjugate (ADC) technology to discover targeted conditioning agents for use with gene editing. The agreement, which is worth up to US$352 M, aligns with Vertex’s strategy to explore new modalities such as gene therapies for the potential treatment of patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).